Close Window
Aetna Aetna
Clinical Policy Bulletin:
Biochemical Markers of Bone Remodeling
Number: 0562


Policy

  1. Aetna considers measurement of serum or urinary collagen crosslinks or other biochemical markers of bone remodeling experimental and investigational for the screening, diagnosis, or management of osteoporosis because the clinical value of these markers has not been established. 

  2. Aetna considers measurement of collagen crosslinks experimental and investigational for screening, diagnosis, or management of bisphosphonate-induced jaw osteonecrosis, chronic kidney disease, osteogenesis imperfecta, or other indications because its clinical value has not been established.

  3. Aetna considers measurements of cobalamins, osteocalcin, sclerostin, and plasma homocysteine for evaluating fracture risk experimental and investigational because their clinical value for this indication has not been established.



Background

Bone strength is affected by its mass, microarchitecture, macrogeometry, and rate of turnover.  Bone remodeling can be assessed by the measurement of surrogate markers of bone turnover in the blood or urine.  Markers of bone formation include bone-specific alkaline phosphatase, osteocalcin (bone Gla-protein), and procollagen I carboxy (PICP) and N-terminal (PINP) extension peptides.  Markers of bone resorption include urinary levels of pyridinolines (Pyr or Pyralink) and deoxypyridinolines (D-Pyr or Pyrilink-D) and serum and urine levels of type I collagen telopeptides (C-telopeptide products (CTX) and N-telopeptide to helix (NTX)).  The level of these markers may identify changes in bone remodeling within a relatively short time interval (several days to months) before changes in bone mineral density can be detected.

Guidelines from the North American Menopause Society (2010) state that "[t]he routine use of biochemical markers of bone turnover in clinical practice is not generally recommended."  The guidelines explain that bone turnover markers vary from day to day, are affected by food intake and time of day, and lack assay standardization, limiting their clinical utility.  Although some clinicians have found that biochemical markers can encourage adherence to therapy, several trials have found no difference in adherence when marker values are communicated to women.

An National Institutes of Health consensus conference concluded that although these biochemical markers of bone turnover may be useful as a research tool, their clinical utility has not been defined: “[A]ccording to available data, marker levels do not predict bone mass or fracture risk and are only weakly associated with changes in bone mass.  Therefore, they are of limited utility in the clinical evaluation of individual patients” (NIH, 2000).

A systemic review of the evidence from the National Osteoporosis Foundation stated that, although biochemical markers of bone remodeling appear promising, these tests vary in sensitivity and specificity and "their appropriate role in patient management is not yet known."  A guideline from the National Osteoporosis Foundation (2003) stated that although biochemical markers have been used to assess risk of fracture, assess bone loss, or monitor response to antiresorptive therapy, “biochemical marker tests cannot replace BMD testing.”  A National Osteoporosis Foundation clinician's guide to the prevention and treatment of osteoporosis (2008) states that "[b]iochemical markers of bone remodeling (resorption and formation) can be measured in the serum and urine in untreated patients to assess risk of fracture," and that "they may predict bone loss" and "may be predictive of fracture risk reduction."  The clinician's guide indicates that although biochemical markers of bone turnover may be predictive of greater mean bone mineral density (BMD) responses when evaluating large groups of patients in clinical trials, the "precision error" of the specific biochemical marker, along with daily and seasonal variability in bone turnover, must be taken into account when evaluating individuals.  Thus, "because of the high degree of biological and analytical variability in measurement of biochemical markers, changes in individuals must be large in order to be clinically meaningful". 

An evidence review for the U.S. Preventive Services Task Force osteoporosis screening guidelines (2002) stated that biochemical markers of bone turnover for osteoporosis screening is "under investigation."

An Agency for Healthcare Research and Quality (AHRQ) technology assessment of diagnosis and monitoring of osteoporosis in women (Nelson et al, 2001) concluded that "[n]o single [biochemical] marker or cluster of markers accurately identified individuals who had osteoporosis, as determined by the results of densitometry.  It is not surprising that agreement between the two tests was poor.  Densitometry measures current bone status, whereas markers measure the process of bone turnover."  The AHRQ assessment concluded that the value of biochemical markers in predicting fracture risk has not been established.  "No marker was associated with increased fracture risk consistently across all studies.  One study provides evidence that using markers in conjunction with densitometry may increase predictability, but this result has not been otherwise confirmed."  The AHRQ found that biochemical markers have not been shown to help select patients for treatment.  "Studies correlating marker results and bone loss indicated no clear trend.  Furthermore, sensitivity and specificity of markers were too low to be useful for the purpose of selecting patients for treatment."  The AHRQ also found that biochemical markers have not been proven to be useful in predicting a patient's response to therapy.  "There is a small correlation between response to therapy as measured by densitometry and marker results, but no marker is accurate enough to reliably identify those individuals who will fail to respond to treatment."  In addition, there are no prospective data showing improved clinical management of patients with other disorders affecting bone resorption and formation (e.g., primary hyperparathyroidism, hyperthyroidism, Paget's disease of the bone, rheumatoid arthritis, renal osteodystrophy, hypogonadism, steroid-induced osteoporosis, etc.) by quantification of collagen crosslinks.

Seibel (2003) noted that the clinical use of bone remodeling markers in individual patients poses considerable problems which so far have not been sufficiently addressed.  Consequently, no scientific or clinical consensus exists as to the use of bone markers in the follow-up of patients with osteoporosis.  Cefalu (2004) stated that although data are beginning to accrue suggesting that changes in bone turnover markers may be an accurate predictor of fracture risk reduction, further research is necessary to elucidate the link between changes in bone turnover markers and bone architecture as a measure of osteoporosis treatment efficacy.  In a review on the clinical use of serum and urine bone markers in the management of osteoporosis, Srivastava, et al (2005) stated that several clinical studies have established the potential utility of markers to identify patients with rapid bone loss, to aid in therapeutic decision-making, and to monitor therapeutic effectiveness of various treatments.  They also noted that elevated marker levels have been demonstrated to be associated with increased risk of fracture in elderly women, but their utility in predicting fracture is not yet established.

Recent evidence demonstrates that bisphosphonates increases bone mineral density (BMD) in the vast majority of patients, so that routine monitoring after initiation of bisphosphonates is not be warranted.  Investigators performed a secondary analysis of data from the Fracture Intervention Trial using a mixed model to evaluate whether alendronate treatment had a fixed effect (i.e., similar for all patients) and, therefore, should not require monitoring, or random effects (i.e., different between individuals) (Bell et al, 2009).  After 3 years, hip BMD increased by a mean of 0.030 g/cm2 in the alendronate group and decreased by a mean of a 0.012 g/cm2 in the placebo group.  Most women in the alendronate group (97.5 %) experienced benefit (i.e., BMD increases 0.019 g/cm2).  Considerable variation in BMD over time among treated patients existed, but this difference was less than the variation within individual patients; furthermore, absolute variation was small.  Baseline BMD, age, body mass index (BMI), or general health did not modify treatment effects.  The investigators concluded that "monitoring bone mineral density in postmenopausal women in the first three years after starting treatment with a potent bisphosphonate is unnecessary and may be misleading."  A commentary on this study (Biggs, 2009) noted that "these results strongly suggest that monitoring BMD after initiation of bisphosphonates is unnecessary.  Ascertaining clinically relevant responses to bisphosphonates is difficult because of variability among patients.  In addition, the beneficial effects of bisphosphonates might extend beyond their ability to increase BMD: Patients in the alendronate group whose BMD did not increase still had lower risk for fragility fractures."  An editorialist (Compston, 2009) stated that "[t]he final nail in the coffin for monitoring bone mineral density is the observation that only a small proportion of reduction in fractures attributable to treatment is explained by a change in bone mineral density.  For example, only 16 % and 4 % of the decrease in the risk of fracture associated with treatment with alendronate or raloxifene, respectively, is attributable to an increase in bone mineral density.  Furthermore, some studies have found similar reductions in fracture regardless of whether bone mineral density increased or decreased on treatment."  The editorialist also noted that there is no evidence that monitoring improves treatment compliance.  "Because adherence with treatment for osteoporosis is poor, it could be argued that monitoring bone mineral density is justified because it should improve adherence and thereby maximise efficacy.  We have no evidence to support this, however, and it would be difficult to identify people who do not adhere with this test because of the large measurement variability.  Because non-adherence occurs mostly within the first three months of starting treatment, early intervention would probably be more effective, and evidence exists that an interview with a healthcare professional a few months after starting treatment improves adherence.  Biochemical markers of bone turnover could potentially be used for monitoring because they change rapidly in response to treatment and are more predictive of fracture reduction.  However, at present within person variability and measurement variability are too great for these markers to be useful in clinical practice."  The editorialist concluded: "If true non-responders to antiresorptive treatment do exist they are rare, and most cases of non-response are caused by failure to persist with treatment.  This is best tackled by carefully explaining the treatment to patients before they start and follow-up after about three months to discuss problems related to treatment.  Routine monitoring of bone mineral density during the first few years of antiresorptive treatment cannot be justified because it may mislead patients, lead to inappropriate management decisions, and waste scarce healthcare resources."

A number of additional evidence-based guidelines and technology assessments have concluded that the clinical utility of measurement of biochemical markers of bone remodeling have not been established.  Guidelines on osteoporosis prevention and treatment from the University of Michigan Health System (2011) make no recommendation for the use of biochemical markers in osteoporosis.  The guidelines state: “Biochemical markers of bone resorption are used in research and may be used clinically to assess the effectiveness of antiresorptive therapy. In the latter setting, a decrease in these markers to premenopausal levels usually occurs after two to three months of therapy.  Some data suggest that elevated levels of bone resorption makers in older women are an independent risk factor for fractures.  However, bone markers are not a reliable predictor of BMD, and are not a substitute for DXA in women at risk.  Generally, their use in the diagnosis of osteoporosis is not recommended.”

An assessment of diagnosis and treatment of osteoporosis by the Swedish Council on Technology Assessment in Health Care (SBU, 2003) concluded that “’[b]iochemical markers are currently a research instrument, and are not used in routine health services.”

Guidelines from the Scientific Advisory Council of the Osteoporosis Society of Canada (Brown et al, 2002) concluded: "Bone turnover markers should not yet be used for routine clinical management.  Additional studies are needed to confirm their use in individual patients."

Guidelines on osteoporosis from the Scottish Intercollegiate Guidelines Network (2007) stated that “[b]iochemical markers of bone turnover should have no role in the diagnosis of osteoporosis or in the selection of patients for BMD measurement.”  Guidelines from the Royal College of Physicians (2002) on glucocorticoid-induced osteoporosis stated that the role of monitoring the effects of bone-sparing agents in glucocorticoid-induced osteoporosis using biochemical markers of bone turnover "has not been established."  The guidelines state that "[r]eported changes in specific resorption markers in response to glucocorticoids have been inconsistent."  The guidelines also note that bone resorption markers may be affected by changes in inflammatory activity and hence a decrease following initiation of glucocorticoid therapy may reflect suppression of disease activity rather than reduced bone resorption.

Royal College of Nursing (2005) guidelines on osteoporosis and menopause stated: "Biochemical markers of bone turnover measured by a urine test are currently being researched and in the future could provide primary care settings with a practical means of monitoring response to treatment."  Royal College of Nursing (2005) guidelines on osteoporosis and breast cancer stated that "biochemical markers of bone turnover detectable in a urine test are currently being investigated."

British Society of Gastroenterology guidelines on osteoporosis in inflammatory bowel disease and celiac disease stated that biochemical markers of bone remodelling "may prove useful in practice to assess the efficacy of treatment and the need to change to another agent" (Lewis and Scott, 2007).  British Society of Gastroenterology guidelines on osteoporosis associated with chronic liver disease stated that "serum bone markers may prove useful in assessing response to treatment in the future in individuals without chronic liver disease" (Collier et al, 2002).  The guidelines stated, however, "as the levels are affected by the extent of hepatic fibrosis and none of these markers has been studied in patients with chronic liver disease, they cannot yet be recommended as a means of assessing bone loss and the risk of fracture in cirrhotic patients."

An assessment by the Australian Medical Services Advisory Committee (MSAC, 2003) of the Ostase test for the mass measurement of serum bone alkaline phosphatase concluded that there is insufficient evidence of the effectiveness and cost-effectiveness of Ostase in the diagnosis and monitoring of osteoporosis.  Guidelines from the Royal Australian College of General Practitioners (O'Neill et al, 2004) stated that biochemical markers of bone remodeling are "rarely needed" in primary care practice.

Guidelines from the Institute for Clinical Systems Improvement (2011) stated that “[a]t this time there is no consensus about the routine use of serum and/or urine markers of bone turnover in the evaluation of patients with osteoporosis.”

Guidelines on osteoporosis from the Kaiser Permanente Care Management Institute (2008) stated: "There is no recommendation for or against routine bone turnover testing with biochemical markers for monitoring women and men taking antiresorptive therapy for osteoporosis."  This conclusion was based upon an "I" grade of evidence, based upon a finding that the evidence that this intervention is effective "is lacking, of poor quality, or conflicting and the balance of benefits, harms, and costs cannot be determined."

A synthesis of guidelines on screening and risk assessment for osteoporosis in post-menopausal women by the National Guideline Clearinghouse (2011) stated: "There is overall agreement that [biochemical markers of bone formation and resorption] do not predict BMD nor reliably estimate fracture risk and that their routine use in clinical practice is not recommended."

Regarding biochemical markers of bone remodeling, guidelines on osteoporosis from the American College of Obstetricians and Gynecologists (2008) stated that "the value of such markers in routine clinical practice has not been established."  Guidelines on menopause and osteoporosis from the Society for Obstetricians and Gynaecologists of Canada (2009) made no recommendation for the use of biochemical markers of bone turnover in the management of osteoporosis.

Guidelines from the American Association of Clinical Endocrinologists (2003) stated that biochemical markers may have a role in fracture risk assessment and monitoring of therapy.  They stated, however, that the role of biochemical markers in clinical management has not been established: "Currently, the precise role of biochemical markers in the clinical management of osteoporosis has not been established.  Several confounding issues must be resolved before a clear role for these measurements can be determined.  Age, gender, menopausal status, meals, diurnal variation, and certain medications all influence resorption marker levels and can cause extreme variability.  Moreover, a relationship has not been demonstrated between changes in bone marker levels after treatment and reduced fracture risk.  In addition, the relationship between changes in bone marker levels and bone balance is unclear."

Guidelines from the World Health Organization (WHO, 2003) stated that changes in biochemical markers at menopause "are insufficiently discriminatory, however, to provide a diagnostic test for osteoporosis", and their use in monitoring individuals "requires further study because of their precision errors and biological variation."  The guidelines concluded that "[b]iochemical indices for skeletal turnover may be useful in risk assessment, but further research is needed to determine their value in clinical practice to monitor treatment."  The guidelines recommended that further research should be carried out on the evaluation of biochemical markers of bone turnover in clinical practice.

American College of Preventive Medicine guidelines on osteoporosis screening (Lim et al, 2009) concluded that biochemical markers "cannot replace BMD testing" and are "not useful for population-based screening".  The guidelines explained that "[t]hese biochemical markers of bone turnover are often used in the research setting but have limited clinical utility."  The guidelines noted that they may be useful in monitoring response to therapy, but that "[t]hey do not predict bone mass or reliably estimate fracture risk."

Guidelines on the use of bisphosphonates in multiple myeloma from the American Society for Clinical Oncology (2007) concluded: "The use of biochemical markers of bone metabolism to monitor bisphosphonate use is not suggested for routine care because of a lack of prospective studies validating such an approach."

A UK National Health Service (NHS Oxfordshire, 2008) statement found insufficient evidence that biochemical monitoring improves compliance or reduces fracture risk.  The statement noted that P1NP is one of a number of biochemical markers of bone turnover that could be measured to monitor compliance and response to drug therapy.  The statement indicated that there are are no trials looking at the role of serum P1NP measurement in the management of any group or sub-group of patients on long-term drug treatment for osteoporosis.  The report described a randomized controlled trial comparing urinary marker measurement with no measurement in post-menopausal women on drug treatment which showed that women who had positive marker results were more likely to persist with treatment than women who did not have marker measurement.  However, women who had negative marker results were more likely to give up treatment than those who had no marker measurement.  The report also cited a small randomized trial on post-menopausal women on drug treatment compared "nurse monitoring" with "urinary marker measurement and nurse monitoring" and "no monitoring".  Patients in the "nurse monitoring" and "marker and nurse monitoring" groups were more likely to persist with treatment than those with "no monitoring".  However, both monitored groups were equally likely to persist, and marker measurement made no difference to compliance.  The statement indicated that there are no trials looking at the role of monitoring by any marker test in specific groups such as patients considering "drug holidays" from long-term treatment or patients on teriparatide treatment.  The statement reported: "There is no trial evidence showing any impact of treatment monitoring (by any method) on fracture rates."  The statement noted the need for appropriately designed studies of the role of monitoring in improving compliance and reducing fracture risk.

The ASCO executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer (Van Poznak et al, 2011) stated that the use of biochemical markers to monitor bone-modifying agents use is not recommended.

Guidelines on screening for osteoporosis in men (Qaseem et al, 2008) and on the pharmacologic treatment of osteoporosis (Qaseem et al, 2008) from the American College of Physicians included no recommendation for the use of biochemical markers.  Guidelines on osteoporosis from the International Society for Clinical Densitometry (ISCD, 2007) and the Michigan Quality Improvement Consortium (2010) also included no recommendation for the use of biochemical markers.  In addition, guidelines from the National Institute for Health and Clinical Excellence (NICE, 2008) on pharmacologic treatments for the prevention of osteoporotic fragility fractures included no recommendation for the use of biochemical markers in diagnosis, selection of therapy, monitoring, fracture risk assessment or any other indication.  

Guidelines on osteoporosis from the British Columbia Medical Services Commission (2011) state, regarding bone turnover markers: "[a]t present no single or combined assay is recommended except in specific circumstances. Assays have a proven use in research studies involving large samples but they are complex and variation is too great to be useful at the individual level."

Medicare's coverage of biochemical markers for osteoporosis is not the result of a systematic evidence review, or a determination by the Agency for Healthcare Research and Quality about the clinical utility of these tests.

The labeling for Food and Drug Administration (FDA)-approved osteoporosis treatments made no recommendation for the use of biochemical markers in the diagnosis of osteoporosis, or in the selection, dosing, or administration of these drugs.

Lee and Suzuki (2010) examined if serum CTX could pre-operatively predict the risk of developing osteonecrosis of the jaws (ONJ) from oral bisphosphonates (BPs).  These researchers hypothesized that there is no clinical correlation between the observed pre-operative serum CTX values and the risk of developing ONJ.  The authors examined the scientific basis (validity) of the morning fasting serum CTX test in 163 consecutive patients who underwent various oral surgery procedures in the office.  The authors also reviewed the laboratory test results and the recommended protocol based on the test values.  A total of 163 patients (mean age of 75.9 years) were divided into 2 groups: (i) group I was the control group that consisted of 109 patients taking oral BPs who did not take the CTX test pre-operatively, and (ii) group 2 consisted of 54 patients taking BPs and who elected to have the CTX test performed to assess their level of risk of developing ONJ, pre-operatively.  Both groups of patients were observed for a period of 8 weeks for signs and symptoms of BP-associated ONJ after surgery.  The clinical data at 8 weeks and beyond revealed that there was no evidence of BP-associated ONJ in all participants.  The authors concluded that the serum CTX is not a valid pre-operative test to accurately assess the level of risk of developing ONJ and is not indicated in the oral surgery patient.

Tolouian et al (2010) evaluated urinary NTX as a marker of bone turnover in chronic kidney disease (CKD).  These investigators studied the relationship between bone-specific alkaline phosphatase (BSAP), parathyroid hormone (PTH) and urine NTX/creatinine (Cr) in 37 CKD out-patients. In a multi-variate model, PTH had a positive correlation with BSAP ( r= 0.44, p < 0.19) and U-NTX/Cr (r = 0.55, p < 0.30), after adjusting for age, gender, estimated glomerular filtration rate (GFR), serum phosphorus, corrected calcium, and race.  However, the strongest correlation was found between the 2 direct markers of bone resorption and formation (U-NTX versus BSAP; r = 0.80; p < 0.0001), suggesting a tight coupling of bone resorption and formation in CKD.  The effect of gender on U-NTX/Cr was studied in a multi-variate model after adjusting for age, race, GFR, serum calcium, phosphorus and PTH.  Females had a higher U-NTX/Cr than males.  The authors concluded that these findings indicated that urinary NTx, a promising marker of bone resorption in CKD patients, exhibits a strong positive correlation with other markers used to assess renal osteodystrophy (i.e., PTH and BSAP).  Unlike PTH and BSAP, urine NTX also measures bone loss secondary to osteoporosis.

Homocysteine (Hcy) is a sulfur amino acid.  Recent studies suggest that Hcy may affect bone metabolism, bone quality as well as fracture risk in humans; and circulating Hcy may be used as a risk indicator for osteoporosis.  Gjesdal et al (2006) reported that plasma total Hcy has been associated with hip fracture, but not directly with BMD.  On the other hand, Morris et al (2005) stated that Hcy and vitamin B12 status indicators are associated with BMD in older Americans.  Whether this association reflects a causal relation remains unclear and merits further study in light of age-related declines in B12 status and BMD, and the need for low-risk, easily implemented strategies for osteoporosis prevention.

There is currently insufficient evidence to support measurements of plasma Hcy for evaluating the risk of fracture.  In fact, Ravaglia et al (2005) reported that low serum folate is responsible for the association between Hcy and risk of osteoporotic fracture in elderly individuals.  Hermann and colleagues (2005) stated that initial findings indicate that Hcy is not only a risk indicator, but also a player in bone metabolism.  Moreover, existing data open speculation that folate, vitamin B6 and vitamin B12 act not only via Hcy-dependent pathways, but also via Hcy-independent pathways.  However, these investigators stated that more studies are needed to clarify the mechanistic role of Hcy, folate, vitamin B6 and vitamin B12 in bone metabolism.  Current evidence-based guidelines make no recommendation for Hcy measurement for diagnosis, monitoring, or risk assessment in osteoporosis.

Gjesdal et al (2006) examined the association of hip BMD with levels of plasma total Hcy (tHcy), folate, and vitamin B12 and the methylenetetrahydrofolate reductase (MTHFR) 677C-->T and 1298A-->C polymorphisms.  Bone mineral density was measured between 1997 and 2000 in 2,268 men and 3,070 women, aged 47 to 50 and 71 to 75 years, from the Hordaland Homocysteine Study cohort.  Low BMD was defined as BMD in the lowest quintile for each sex and age group.  Linear, logistic, and generalized additive regression models were used.  Plasma levels of tHcy were inversely related to BMD among middle-aged and elderly women (p < 0.001) but not among men.  The multiple adjusted odds ratio for low BMD among subjects with high greater than or equal to 15 uM/L [greater than or equal to 2.02 mg/L]) compared with low (less than 9 uM/L [less than 1.22 mg/L]) tHcy level was 1.96 (95 % confidence interval [CI]: 1.40 to 2.75) for women and was not significant for men.  Additional adjustments for plasma folate level or intake of calcium and vitamin D did not substantially alter the results.  Plasma folate level was associated with BMD in women only.  The authors observed no association between BMD and vitamin B12 level or the MTHFR polymorphisms; and they concluded that elevated tHcy and low folate levels were associated with reduced BMD in women but not in men.  These findings suggest that tHcy may be a potential modifiable risk factor for osteoporosis in women.

Selhub (2006) stated that data from several studies suggest that mild elevation of plasma Hcy is a risk factor for occlusive vascular disease.  In the Framingham studies it was shown that plasma tHcy concentration is inversely related to the intake and plasma levels of folate and vitamin B-6 as well as vitamin B-12 plasma levels.  Almost 2/3 of the prevalence of high Hcy is attributable to low vitamin status or intake.  Elevated plasma Hcy concentration is a risk factor for prevalence of extra-cranial carotid artery stenosis of at least 25 % in both men and women.  Prospectively elevated plasma Hcy is associated with increased total and cardiovascular diseases mortality, increased incidence of stroke, increased incidence of dementia and Alzheimer's disease, increased incidence of bone fracture, and higher prevalence of chronic heart failure.  This multitude of relationships between elevated plasma tHcy and diseases that afflict the elderly points to the existence of a common denominator that may be responsible for these diseases.  Whether this denominator is Hcy itself or whether Hcy is merely a marker remains to be determined.  This is in agreement with the editorial of van Meurs and Uitterlinden (2005) who stated that "despite the potential limitations of the study by Sato et al (2005), the results show that at least in patients following stroke, folate and vitamin B12 supplementation is effective in preventing hip fracture.  Whether a similar effect can also be obtained in other (high fracture risk) patients can only be answered by other interventional studies.  After the initial observation of association between circulating homocysteine levels and fracture risk less than 1 year ago, these results now support a causal link.  However, final proof of causality will have to come from elucidation of the biological mechanism underlying this relationship".

Perier and colleagues (2007) noted that Hcy has recently been described as an independent risk factor for osteoporotic fractures in the elderly.  These investigators prospectively followed women belonging to the OFELY study during a mean follow-up of 10 years.  Homocysteine was measured at baseline in 671 post-menopausal women from the OFELY cohort (mean age of 62.2 +/- 9 years).  Incident clinical fractures were recorded during annual follow-up and vertebral fractures were evaluated with radiographs every 4 years.  A Cox proportional hazards model based on time to first fracture was used to calculate hazard ratios for quartiles of Hcy values.  Mean Hcy was 10.6 +/- 3.4 mumol/L, increasing with age.  After adjustment for age, Hcy was significantly associated with physical activity, calcium intake, serum albumin and serum creatinine; but not with bone turnover markers and BMD.  During a mean follow-up of 10 years, 183 fractures occurred among 134 women.  After adjustment for age, the overall relative risk of fracture for each 1 SD increment of Hcy was 1.03 (95 % CI: 0.87 to 1.31).  Fracture risk was higher in women with Hcy in the highest quartile without adjustment but no longer after adjustment for age.  The authors concluded that Hcy is not an independent risk factor of osteoporotic fractures in healthy post-menopausal women from the OFELY cohort with a broad age range.

Rhew et al (2008) examined the relationship of baseline Hcy levels with BMD and incidence of fractures over 2 years in women with and without systemic lupus erythematosus (SLE).  Women with SLE (n = 100) and without SLE (n = 100) were matched according to age (+/- 5 years), race, and menopausal status.  Data were collected from 1997 to 2004, including hip, lumbar spine (L-spine), and distal forearm BMD, serum Hcy levels, and a self-administered questionnaire on osteoporosis risk factors, medications and symptomatic fractures at baseline and 2-year follow-up.  Analyses were performed to compare Hcy levels, BMD, and incident fractures and to evaluate the relationship of Hcy with BMD and incident fractures in both groups.  Mean Hcy +/- SD was higher (p < 0.001) in women with SLE (9.88 +/- 3.8 micromol/L) than in women without SLE (7.98 +/- 2.6 micromol/L).  Women with SLE had significantly lower L-spine BMD Z-scores, while hip BMD Z-scores and distal forearm BMD T-scores were non-significantly lower than in women without SLE.  No significant correlations were observed between Hcy and BMD in either group.  A total of 13 women with SLE experienced new fractures, while 4 women without SLE had new fractures over 2 years (p = 0.035); however, there was no association between Hcy levels and incident fractures in either group.  The authors concluded that women with SLE had significantly greater baseline Hcy, lower L-spine BMD, and more new fractures over 2 years, compared with women without SLE.  However, Hcy levels were not significantly associated with BMD and did not predict new fractures in women with or without SLE over 2 years.

Zhu et al (2009) examined the effects of Hcy and MTHFR genotype on hip bone loss (as indexed by BMD) and fracture risk over 5 years in a cohort of 1,213 community-dwelling women aged 70 to 85 years.  Nutritional intake and prevalent fracture status were assessed at baseline, plasma Hcy was measured at year 1, and hip dual-energy X-ray absorptiometry (DXA) BMD was measured at years 1 and 5.  Clinical incident osteoporotic fractures confirmed by radiographical report were collected throughout the study and the MTHFR gene C677T and A1298C polymorphisms genotyped.  Data were analyzed using analysis of co-variance and Cox proportional hazard regression.  The highest tertile of Hcy was associated with a greater hip BMD loss over 4 years (-2.8 %) compared to the middle (-1.6 %) and lowest tertiles (-1.2 %) (p < 0.001).  This effect remained after adjustment for co-variates.  There was no effect of Hcy on fracture prevalence or incidence.  Gene variation in MTHFR was only weakly related to one of the bone outcome measures.  The authors concluded that in this study population, high Hcy is associated with greater hip bone loss but not fracture risk.

Vasikaran and associates (2011) determined the clinical potential of bone turnover markers (BTMs) in the prediction of fracture risk and for monitoring the treatment of osteoporosis.  Evidence from prospective studies was gathered through literature review of the PUBMED database between the years 2000 and 2010 and the systematic review of the Agency for Healthcare Research and Quality up to 2001.  High levels of BTMs may predict fracture risk independently from BMD in post-menopausal women.  They have been used for this purpose in clinical practice for many years, but there is still a need for stronger evidence on which to base practice.  Bone turnover markers provide pharmacodynamic information on the response to osteoporosis treatment, and as a result, they are widely used for monitoring treatment in the individual.  However, their clinical value for monitoring is limited by inadequate appreciation of the sources of variability, by limited data for comparison of treatments using the same BTMs and by inadequate quality control.  The International Osteoporosis Foundation and the International Federation of Clinical Chemistry and Laboratory Medicine recommend one bone formation marker (serum procollagen type I N propeptide [PINP]) and one bone resorption marker (serum CTX) to be used as reference markers and measured by standardized assays in observational and intervention studies in order to compare the performance of alternatives and to enlarge the international experience of the application of markers to clinical medicine.  The authors concluded that BTMs hold promise in fracture risk prediction and for monitoring treatment.  Uncertainties over their clinical use can be in part resolved by adopting international reference standards.

Funck-Brentano et al (2011) stated that serum BTMs (sBTMs) are used in clinical practice for patients undergoing post-menopausal osteoporosis therapy.  These researchers analyzed the literature on the ability of sBTMs to monitor therapy, focusing on the following 5 objectives: (i) pre-treatment values and treatment choice; (ii) short-term changes and clinical response; (iii) sBTMs effect on persistence to therapy; (iv) sBTMs ability to predict fracture risk after withdrawal of therapy; and (v) the prediction of serious adverse effects.  A systematic search on Medline completed manually was performed until November 2010 and was limited to post-menopausal osteoporosis and marketed therapies.  Following the PRISMA statement for systematic reviews, a total of 48 studies were selected.  Baseline sBTMs levels were not able to predict fracture risk reduction with either treatment.  There was more evidence for the prediction of fracture risk reduction with bone formation sBTMs including PINP than with serum CTX.  Most of the studies found correlations between sBTMs and BMD changes under anti-resorptive therapies, although inconsistently.  The only published study on the impact of sBTMs on persistence to therapy showed negative results.  There was no evidence that sBTMs allow the prediction of adverse effects, especially osteonecrosis of the jaw.  The authors concluded that sBTMs reflect the skeletal effects of anti-osteoporotic treatments.  Pre-treatment values are not recommended for selecting therapy.  Short-term changes are significantly correlated with BMD variation, but there is no published evidence that they predict benefit on fracture risk at the individual level.

Biver and colleagues (2012) noted that osteoporosis diagnosis is based on BMD but bone remodeling is also a crucial issue.  It can be assessed by BTMs.  Their interest for the positive and etiological diagnosis of osteoporosis at baseline, and their predictive value for past asymptomatic vertebral fractures, were evaluated by a systematic review of the literature.  Medline database was searched to identify all published reports analyzing BTMs and BMD or fractures.  These investigators conducted meta-analyses on BTMs levels according to osteoporotic status using random effects models.  Moderate and negative correlations were found, mainly in post-menopausal women, between BTMs and BMD, especially with bone alkaline phosphatase (bone ALP), osteocalcin, serum C-terminal and urine N-terminal cross-linking telopeptides of type I collagen (serum CTX and urine NTX).  Bone ALP and serum CTX levels are higher in osteoporotic patients compared to controls.  High levels of bone ALP in primary hyper-parathyroidism and low levels of osteocalcin in endogenous hypercorticism are the most relevant data reported in endocrine diseases associated with osteoporosis.  High levels of BTMs, especially osteocalcin, bone ALP or serum CTX, may be associated with prevalent vertebral fractures.  The authors concluded that the diagnostic value of BTMs at baseline in osteoporosis is very low.  The interest of BTMs for the etiological diagnosis of secondary osteoporosis has not been demonstrated.  Furthermore, they stated that data are lacking to address the interest of BTMs assessment to screen for vertebral fractures in asymptomatic patients with high-risk factors of fractures.

An UpToDate review on “Use of biochemical markers of bone turnover in osteoporosis” (Rosen, 2013) states that “The use of biochemical bone turnover markers (BTMs) in clinical trials has been helpful in understanding the mechanism of action of therapeutic agents.  However, their role in the care of individual patients is not well established.  Biologic and laboratory variability in BTM values have confounded their widespread use in clinical practice …. There is no consensus on a role for BTMs in the diagnosis of osteoporosis or the selection of candidates for therapy.  There is currently insufficient data to support the use of BTMs for deciding when to restart bisphosphonate therapy after a drug holiday or for the assessment of risk (osteonecrosis of the jaw) in bisphosphonate-treated patients undergoing invasive dental procedures”. 

Garnero et al (2013) stated that sclerostin, an osteocyte soluble factor, is a key regulator of bone formation.  Circulating sclerostin levels were reported to increase with age and to be modestly associated with BMD and bone turnover, but there are no data on the association with fracture risk.  In a population of 572 post-menopausal women (mean age of 67 years) followed prospectively for a median of 6 years, there was no significant association between baseline levels of serum sclerostin and incidence of all fractures that occurred in 64 subjects.  These researchers investigated 572 post-menopausal women (mean age of 67 ± 8.5 years) from the OFELY population-based cohort.  The associations of serum sclerostin measured with a new 2-site ELISA and spine and hip BMD by DXA, serum β-isomerized CTX, intact N-terminal PINP, intact PTH, 25-hydroxyvitamin D [25(OH)D], estradiol, testosterone, and fracture risk were analyzed.  At the time of sclerostin measurements, 98 post-menopausal women had prevalent fractures.  After a median of 6 years (interquartile range, 5 to 7 years) follow-up, 64 post-menopausal sustained an incident fracture.  Serum sclerostin correlated positively with spine (r = 0.35, p < 0.0001) and total hip (r = 0.25, p < 0.0001) BMD.  Conversely, serum sclerostin was weakly negatively associated with the bone markers PINP (r = -0.10, p = 0.014) and CTX (r = -0.13, p = 0.0026) and with intact PTH (r = -0.13, p = 0.0064).  There was no significant association of serum sclerostin with 25(OH)D, estradiol, free estradiol index, or testosterone.  Serum sclerostin considered as a continuous variable or in quartiles was not significantly associated with the risk of prevalent or incident fracture.  The authors concluded that serum sclerostin is weakly correlated with BMD, bone turnover, and PTH in post-menopausal women.  It was not significantly associated with the risk of all fractures, although the number of incident fractures recorded may not allow detecting a modest association.

In a prospective cohort study, Amrein et al (2014) evaluated the association between levels of circulating sclerostin and laboratory parameters of bone and mineral metabolism, BMD and quality measured using quantitative ultrasound (QUS), fracture risk, and mortality.  Female nursing home residents aged 70 and older (mean 84 ± 6; n = 539) included in this study.  Serum sclerostin, bone turnover markers, and BMD and quality were measured at baseline.  Participants were followed for clinical fractures and all-cause mortality.  Partial correlation analysis adjusted for age, weight, and renal function revealed a significant positive correlation between sclerostin levels and calcaneal stiffness and radial and phalangeal speed of sound (all p < 0.01) and a significant negative correlation between sclerostin levels and osteocalcin, serum CTX, and PTH (p < 0.05).  After a mean follow-up of 27 ± 8 months, 139 participants (26 %) had died and 64 had a hip or other non-vertebral fracture (12 %).  Sclerostin was not predictive of mortality.  In women with a negative fracture history, it was significantly but not linearly associated with fracture risk.  The authors concluded that in institutionalized elderly women, there is a significant relationship between serum sclerostin levels and QUS indices, bone turnover, and PTH, but sclerostin was not strongly associated with important clinical outcomes.  Thus, it remains unclear whether sclerostin is a clinically useful predictor of fractures or mortality, at least in this setting.

Lewerin et al (2014) noted that cobalamin deficiency in elderlies may affect bone metabolism.  These researchers examined if serum cobalamins or holotranscobalamin (holoTC; the metabolic active cobalamin) predicts incident fractures in old men.  Men participating in the Gothenburg part of the population-based Osteoporotic Fractures in Men (MrOS) Sweden cohort and without ongoing vitamin B medication were included in the present study (n = 790; age range of 70 to 81 years).  During an average follow-up of 5.9 years, 110 men sustained X-ray-verified fractures including 45 men with clinical vertebral fractures.  The risk of fracture (adjusted for age, smoking, BMI, BMD, falls, prevalent fracture, tHcy, cystatin C, 25(OH)D, intake of calcium, and physical activity (fully adjusted)), increased per each standard deviation decrease in cobalamins (hazard ratio (HR), 1.38; 95 % CI: 1.11 to 1.72) and holoTC (HR, 1.26; 95 % CI: 1.03 to 1.54), respectively.  Men in the lowest quartile of cobalamins and holoTC (fully adjusted) had an increased risk of all fracture (cobalamins, HR = 1.67 (95 % CI: 1.06 to 2.62); holoTC, HR = 1.74 (95 % CI: 1.12 to 2.69)) compared with quartiles 2 to 4.  No associations between folate or tHcy and incident fractures were seen.  The authors presented novel data showing that low levels of holoTC and cobalamins predicting incident fracture in elderly men.  This association remained after adjustment for BMI, BMD, tHcy, and cystatin C.  However, any causal relationship between low cobalamin status and fractures should be explored in a prospective treatment study.

 
CPT Codes / HCPCS Codes / ICD-9 Codes
CPT codes not covered for indications listed in the CPB:
0103T
82523
82607
82608
83090
83937
Other CPT codes related to the CPB:
76977
77078
77080 - 77082
84075 - 84080
ICD-9 codes not covered for indications listed in the CPB (not all-inclusive):
242.00 - 242.91 Thyrotoxicosis with or without goiter
252.01 Primary hyperparathyroidism
253.4 Other anterior pituitary disorders
256.39 Other ovarian failure
257.2 Other testicular hypofunction
588.0 Renal osteodystrophy
627.2 Symptomatic menopausal or female climacteric states
714.0 - 714.9 Rheumatoid arthritis and other inflammatory polyarthropathies
731.0 Osteitis deformans without mention of bone tumor
733.10 - 733.19 Pathologic fracture
733.90 Disorder of bone and cartilage, unspecified
733.93 - 733.95 Stress fracture
733.99 Other disorders of bone and cartilage
800.00 - 829.1 Fracture of bone
V49.81 Asymptomatic postmenopausal status (age-related) (natural)
V82.89 Special screening for other specified conditions


The above policy is based on the following references:
  1. No authors listed. Osteoporosis prevention, diagnosis, and therapy. NIH Consens Statement. 2000;17(1):1-45.
  2. No authors listed. Osteoporosis: Review of the evidence for prevention, diagnosis, and treatment and cost-effectiveness analysis. Introduction. Osteoporos Int. 1998;8 Supp 4:S7-S80.
  3. Garnero P, Delmas PD. New developments in biochemical markers to fracture risk. Calcif Tissue Int.1996;59(Suppl 1):S2-S9.
  4. Adachi JD. The correlation of bone mineral and biochemical markers to fracture risk. Calcif Tissue Int. 1996;59(Suppl 1):S16-S19.
  5. Garnero P, Hausherr E, Chapuy MC, et al. Markers of bone resorption predict hip fracture in elderly women: The EPIDOS prospective study. J Bone Miner Res. 1996;11:1531-1538.
  6. Seibel MJ, Woitge H, Scheidt-Nave C, et al. Urinary hydroxypyridinium crosslinks of collagen in population-based screening for overt vertebral osteoporosis: Results of a pilot study. J Bone Miner Res. 1994;9:1433-1440.
  7. Akesson K, Ljunghall S, Jonson B, et al. Assessment of biochemical markers of bone metabolism in relation to the occurrence of fracture. A retrospective and prospective population-based study of women. J Bone Miner Res. 1995;10:1823-1829.
  8. Riggs BL, Melton LJ III, O'Fallon WM. Drug therapy for vertebral fractures in osteoporosis: Evidence that decreases in bone turnover and increases in bone mass both determine antifracture efficacy. Bone. 1996;18(Suppl):197S-201S.
  9. Hansen MA, Overgaard K, Riis BJ, et al. Role of peak bone mass and bone loss in postmenopausal osteoporosis: 12-year study. BMJ. 1991;303:961-964.
  10. Garnero P, Delmas PD. Biochemical markers of bone turnover. Applications for osteoporosis. Endocrinol Metab Clin. 1998;27(2):303-323.
  11. Woitge HW, Seibel MJ. Osteoporosis. Biochemical markers to survey bone turnover. Rheum Dis Clin North Am. 2001;27(1):49-80.
  12. Nelson HD, Morris CD, Kraemer DF, et al. Osteoporosis in postmenopausal women: Diagnosis and monitoring. Report Summary. Evidence Report/Technology Assessment, No. 28. Pub. No. AHRQ 01-E031. Rockville, MD: Agency for Healthcare Research and Quality (AHRQ); February 2001. Available at: http://www.ahcpr.gov/clinic/osteosum.htm. Accessed September 10, 2001.
  13. Szulc P, Delmas PD. Biochemical markers of bone turnover in men. Calcif Tissue Int. 2001;69(4):229-234.
  14. Ebeling PR, Akesson K. Role of biochemical markers in the management of osteoporosis. Best Pract Res Clin Rheumatol. 2001;15(3):385-400.
  15. Institute for Clinical Systems Improvement (ICSI). Biochemical markers for bone turnover in osteoporosis. Technology Assessment Report No. 53. Bloomington, MN: ICSI; February 2001.
  16. Nelson HD, Helfand M. Screening for postmenopausal osteoporosis. Rockville, MD: Agency for Healthcare Research and Quality (AHRQ); 2002.
  17. U.S. Preventive Services Task Force (USPSTF). Screening for postmenopausal osteoporosis. In: Guide to Clinical Preventive Services. Report of the U.S. Preventive Services Task Force. Rockville, MD: USPSTF; September 2002.
  18. Brown JP, Josse RG; Scientific Advisory Council of the Osteoporosis Society of Canada. 2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. CMAJ. 2002;167(10 Suppl):S1-S34.
  19. Tannenbaum C, Clark J, Schwartzman K, et al. Yield of laboratory testing to identify secondary contributors to osteoporosis in otherwise healthy women. J Clin Endocrinol Metab. 2002;87(10):4431-4437.
  20. Royal College of Physicians. Glucocorticoid-induced osteoporosis. Guidelines for Prevention and Treatment. London, UK: Royal College of Physicians of London; December 2002.
  21. Hodgson SF, Watts NB, Bilezikian JP, et al. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the prevention and treatment of postmenopausal osteoporosis: 2001 edition, with selected updates for 2003. Endocr Pract. 2003;9:544–564.
  22. Robins SP. Collagen turnover in bone diseases. Curr Opin Clin Nutr Metab Care. 2003;6(1):65-71.
  23. Seibel MJ. Biochemical markers of bone metabolism in the assessment of osteoporosis: Useful or not? J Endocrinol Invest. 2003;26(5):464-471.
  24. Cefalu CA. Is bone mineral density predictive of fracture risk reduction? Curr Med Res Opin. 2004;20(3):341-349.
  25. Brigham and Women's Hospital. Osteoporosis. Guide to prevention, diagnosis, and treatment. Boston, MA: Brigham and Women's Hospital; 2001.
  26. O'Neill S, MacLennan A, Bass S, et al; Osteoporosis Australia Medical Scientific Committee. Guidelines for the management of postmenopausal osteoporosis for GPs. Aust Fam Physician. 2004;33(11):910-919.
  27. University of Michigan Health System. Osteoporosis: Prevention and treatment. Guidelines for Clinical Care. Ann Arbor, MI: University of Michigan Health System; December 2011.
  28. Swedish Council on Technology Assessment in Health Care (SBU). Osteoporosis - prevention, diagnosis and treatment. A systematic literature review. Summary and Conclusions. Stockholm, Sweden: SBU; October 2003.
  29. Medical Services Advisory Committee (MSAC). OSTASE immunoassay for the mass measurement of serum bone alkaline phosphatase. MSAC Application 1044. Canberra, ACT: MSAC; 2003.
  30. National Osteoporosis Foundation. Physician's guide to prevention and treatment of osteoporosis. Washington, DC: National Osteoporosis Foundation; April 2003.
  31. Michigan Quality Improvement Consortium. Management and prevention of osteoporosis. Michigan Quality Improvement Consortium Guideline. Southfield, MI: Michigan Quality Improvement Consortium; January 2010.
  32. Scottish Intercollegiate Guidelines Network (SIGN). Management of osteoporosis. A national clinical guideline. SIGN Publication No. 71. Edinburgh, Scotland: SIGN; June 2003 (reaffirmed 2007).
  33. American Medical Directors Association (AMDA). Osteoporosis. Columbia, MD: AMDA; 2003.
  34. Institute for Clinical Systems Improvement (ICSI). Diagnosis and treatment of osteoporosis. Health Care Guideline. Bloomington, MN: Institute for Clinical Systems Improvement (ICSI); July 2011.
  35. Simsek B, Karacaer O, Karaca I. Urine products of bone breakdown as markers of bone resorption and clinical usefulness of urinary hydroxyproline: An overview. Chin Med J (Engl). 2004;117(2):291-295.
  36. Nishizawa Y, Nakamura T, Ohta H, et al. Guidelines for the use of biochemical markers of bone turnover in osteoporosis (2004). J Bone Miner Metab. 2005;23(2):97-104.
  37. Srivastava AK, Vliet EL, Lewiecki EM, et al. Clinical use of serum and urine bone markers in the management of osteoporosis. Curr Med Res Opin. 2005;21(7):1015-1026.
  38. Sato Y, Honda Y, Iwamoto J, et al. Effect of folate and mecobalamin on hip fractures in patients with stroke: A randomized controlled trial. JAMA. 2005;293(9):1082-1088.
  39. van Meurs JB, Uitterlinden AG. Homocysteine and fracture prevention. JAMA. 2005;293(9):1121-1122.
  40. Ravaglia G, Forti P, Maioli F, et al. Folate, but not homocysteine, predicts the risk of fracture in elderly persons. J Gerontol A Biol Sci Med Sci. 2005;60(11):1458-1462.
  41. Herrmann M, Widmann T, Herrmann W. Homocysteine--a newly recognised risk factor for osteoporosis. Clin Chem Lab Med. 2005;43(10):1111-1117.
  42. Morris MS, Jacques PF, Selhub J. Relation between homocysteine and B-vitamin status indicators and bone mineral density in older Americans. Bone. 2005;37(2):234-242.
  43. Gjesdal CG, Vollset SE, Ueland PM, et al. Plasma total homocysteine level and bone mineral density: The Hordaland Homocysteine Study. Arch Intern Med. 2006;166(1):88-94.
  44. Selhub J. The many facets of hyperhomocysteinemia: Studies from the Framingham cohorts. J Nutr. 2006;136(6 Suppl):1726S-1730S.
  45. World Health Organization (WHO). Prevention and management of osteoporosis. Report of a WHO Scientific Group. WHO Technical Report Series No. 921. Geneva, Switzerland: World Health Organization; 2003.
  46. Royal College of Nursing. Women’s health and the menopause. RCN guidance for nurses, midwives and health visitors. London, UK: Royal College of Nursing; revised April 2005.
  47. Royal College of Nursing. Osteoporosis and bone health. Optimum care of osteoporosis and bone metastases in people affected by breast cancer. London, UK: Royal College of Nursing; August 2005.
  48. Collier JD, Ninkovic M, Compston JE. Guidelines on the management of osteoporosis associated with chronic liver disease. Gut. 2002;50 Suppl 1:i1-9.
  49. Lewis NR, Scott BB. Guidelines for osteoporosis in inflammatory bowel disease and coeliac disease. BSG Guidelines in Gastroenterology. London, UK: British Society of Gastroenterology (BSG); June 2007.
  50. North American Menopause Society. Management of postmenopausal osteoporosis: Position statement of the North American Menopause Society. Menopause. 2002;9(2):84-101.
  51. North American Menopause Society. Management of osteoporosis in postmenopausal women: 2006 position statement of The North American Menopause Society. Menopause. 2006;13(3):340-367.
  52. North American Menopause Society. Management of osteoporosis in postmenopausal women: 2010 position statement of The North American Menopause Society. Menopause. 2010;17(1):25-54.
  53. Cremers S, Garnero P. Biochemical markers of bone turnover in the clinical development of drugs for osteoporosis and metastatic bone disease: Potential uses and pitfalls. Drugs. 2006;66(16):2031-2058.
  54. Périer MA, Gineyts E, Munoz F, et al. Homocysteine and fracture risk in postmenopausal women: The OFELY study. Osteoporos Int. 2007;18(10):1329-1336.
  55. Green TJ, McMahon JA, Skeaff CM, et al. Lowering homocysteine with B vitamins has no effect on biomarkers of bone turnover in older persons: A 2-y randomized controlled trial. Am J Clin Nutr. 2007;85(2):460-464.
  56. International Society for Clinical Densitometry (ISCD). 2007 Official Positions of the International Society for Clinical Densitometry. ISCD Official Positions. West Hartford, CT: ISCD; October 2007.
  57. Cagnacci A, Bagni B, Zini A, et al. Relation of folates, vitamin B12 and homocysteine to vertebral bone mineral density change in postmenopausal women. A five-year longitudinal evaluation. Bone. 2008;42(2):314-320.
  58. Rhew EY, Lee C, Eksarko P, Dyer AR, et al. Homocysteine, bone mineral density, and fracture risk over 2 years of followup in women with and without systemic lupus erythematosus. J Rheumatol. 2008;35(2):230-236.
  59. National Osteoporosis Foundation (NOF). Clinician's guide to prevention and treatment of osteoporosis. BoneSource for Professionals. Washington, DC: NOF; 2008. Available at: http://www.nof.org/professionals/NOF_Clinicians_Guide.pdf. Accessed June 29, 2009.
  60. National Institute for Health and Clinical Excellence (NICE). Alendronate, etidronate, risedronate, raloxifene and strontium ranelate for the primary prevention of osteoporotic fragility fractures in postmenopausal women. Technology Appraisal Guidance No. 160. London, UK: National Institute for Health and Clinical Excellence (NICE); October 2008.
  61. National Institute for Health and Clinical Excellence (NICE). Alendronate, etidronate, risedronate, raloxifene, strontium ranelate and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women. Technology Appraisal Guidance No. 161. London, UK: National Institute for Health and Clinical Excellence (NICE); October 2008.
  62. Shiraki M, Kuroda T, Tanaka S, et al. Nonenzymatic collagen cross-links induced by glycoxidation (pentosidine) predicts vertebral fractures. J Bone Miner Metab. 2008;26(1):93-100.
  63. Zhu K, Beilby J, Dick IM, et al. The effects of homocysteine and MTHFR genotype on hip bone loss and fracture risk in elderly women. Osteoporos Int. 2009;20(7):1183-1191.
  64. Lim LS, Hoeksema LJ, Sherin K; ACPM Prevention Practice Committee. Screening for osteoporosis in the adult U.S. population: ACPM position statement on preventive practice. Am J Prev Med. 2009;36(4):366-375.
  65. Society for Obstetricians and Gynaecologists of Canada (SOGC). Bone health. In: Menopause and osteoporosis update 2009. J Obstet Gynaecol Can. 2009;31(1 Suppl 1):S34-41.
  66. Bell KJ, Hayen A, Macaskill P, et al. Value of routine monitoring of bone mineral density after starting bisphosphonate treatment: Secondary analysis of trial data. BMJ. 2009;338:b2266.
  67. Biggs WS. Is monitoring BMD necessary in patients who take bisphosphonates? JWatch Women's Health, July 23, 2009.
  68. Compston J. Monitoring bone mineral density during antiresorptive treatment for osteoporosis. Is potentially misleading and a misuse of healthcare resources. BMJ. 2009;338:b1276.
  69. UK National Health Service (NHS), Oxfordshire Primary Care Trust, South Central Priorities Committee. Serum P1NP measurement in the management of osteoporosis. Policy Statement 114. Ref TV111. Oxford, UK: NHS; March 2008.
  70. Qaseem A, Snow V, Shekelle P, et al.; Clinical Efficacy Assessment Subcommittee of the American College of Physicians. Screening for osteoporosis in men: A clinical practice guideline from the American College of Physicians. Ann Intern Med. 2008;148:680-684.
  71. Qaseem A, Snow V, Shekelle P, et al.; Clinical Efficacy Assessment Subcommittee of the American College of Physicians. Pharmacologic treatment of low bone density or osteoporosis to prevent fractures: A clinical practice guideline from the American College of Physicians. Ann Intern Med. 2008;149(6):404-415.
  72. American College of Obstetricians and Gynecologists (ACOG). Osteoporosis. Washington, DC: American College of Obstetricians and Gynecologists (ACOG); January 2004 (reaffirmed 2008).
  73. Kaiser Permanente Care Management Institute. Osteoporosis/fracture prevention clinical practice guidelines. Oakland, CA: Kaiser Permanente Care Management Institute; November 2008.
  74. Lee CY, Suzuki JB. CTX biochemical marker of bone metabolism. Is it a reliable predictor of bisphosphonate-associated osteonecrosis of the jaws after surgery? Part II: A prospective clinical study. Implant Dent. 2010;19(1):29-38.
  75. Tolouian R, Hernandez GT, Chiang WY, Gupta A. A new approach for evaluating bone turnover in chronic kidney disease. Eur J Intern Med. 2010;21(3):230-232.
  76. National Guideline Clearinghouse (NGC). Guideline synthesis: Screening and risk assessment for osteoporosis in postmenopausal women. In: National Guideline Clearinghouse (NGC) [website]. Rockville, MD: Agency for Healthcare Research and Quality (AHRQ); 2011.
  77. Van Poznak CH, Temin S, Yee GC, et al; American Society of Clinical Oncology. American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer. J Clin Oncol. 2011;29(9):1221-1227.
  78. Vasikaran S, Eastell R, Bruyere O, et al; IOF-IFCC Bone Marker Standards Working Group. Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: A need for international reference standards. Osteoporos Int. 2011;22(2):391-420.
  79. Funck-Brentano T, Biver E, Chopin F, et al. Clinical utility of serum bone turnover markers in postmenopausal osteoporosis therapy monitoring: A systematic review. Semin Arthritis Rheum. 2011;41(2):157-169.
  80. Medical Services Commission. Osteoporosis: Diagnosis, treatment and fracture prevention. Vancouver, BC: British Columbia Medical Services Commission; May 1, 2011.
  81. Biver E, Chopin F, Coiffier G, et al. Bone turnover markers for osteoporotic status assessment? A systematic review of their diagnosis value at baseline in osteoporosis. Joint Bone Spine. 2012;79(1):20-25.
  82. Rosen HN. Use of biochemical markers of bone turnover in osteoporosis. Last reviewed May 2013. UpToDate Inc. Waltham, MA.
  83. van Wijngaarden JP, Doets EL, Szczecinska A, et al. Vitamin B12, folate, homocysteine, and bone health in adults and elderly people: A systematic review with meta-analyses. J Nutr Metab. 2013;2013:486186.
  84. Garnero P, Sornay-Rendu E, Munoz F, et al. Association of serum sclerostin with bone mineral density, bone turnover, steroid and parathyroid hormones, and fracture risk in postmenopausal women: The OFELY study. Osteoporos Int. 2013;24(2):489-494.
  85. Amrein K, Dobnig H, Wagner D, et al.  Sclerostin in institutionalized elderly women: Associations with quantitative bone ultrasound, bone turnover, fractures, and mortality. J Am Geriatr Soc. 2014 Apr 29. [Epub ahead of print]
  86. Lewerin C, Nilsson-Ehle H, Jacobsson S, et al. Low holotranscobalamin and cobalamins predict incident fractures in elderly men: The MrOS Sweden. Osteoporos Int. 2014;25(1):131-140.


email this page   


Copyright Aetna Inc. All rights reserved. Clinical Policy Bulletins are developed by Aetna to assist in administering plan benefits and constitute neither offers of coverage nor medical advice. This Clinical Policy Bulletin contains only a partial, general description of plan or program benefits and does not constitute a contract. Aetna does not provide health care services and, therefore, cannot guarantee any results or outcomes. Participating providers are independent contractors in private practice and are neither employees nor agents of Aetna or its affiliates. Treating providers are solely responsible for medical advice and treatment of members. This Clinical Policy Bulletin may be updated and therefore is subject to change.
Aetna
Back to top